专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008118762A9 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：使用IMIQUIMOD治疗患有皮肤疾病的儿童治疗儿童时的安全性的方法和包装
公开(公告)号：WO2008118762A9
公开(公告)日：2011-01-06
申请号：PCT/US2008057758
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS LLC , SLADE HERBERT B , LEE JAMES H
发明人： SLADE HERBERT B , LEE JAMES H
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat chiidren affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*109/L or a decrease in median absolute neutrophil count by about 1.42*109/L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatologica! disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了用于增强咪喹莫特用于治疗受皮肤疾病影响的儿童的安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4 * 109 / L或中位绝对嗜中性粒细胞计数降低约1.42 * 109 / L。咪喹莫特的局部和/或透皮给药，包括霜剂，软膏，凝胶，洗剂，药膏和压敏胶粘剂组合物以治疗皮肤病！公开了儿童疾病，即传染性软体动物，病毒感染，例如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

2. 发明申请

WO2006073940A3 MULTI-ROUTE ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS 审中-公开
标题翻译：免疫应答改性剂化合物的多路径管理
公开(公告)号：WO2006073940A3
公开(公告)日：2006-11-30
申请号：PCT/US2005047069
申请日：2005-12-28
申请人： 3M INNOVATIVE PROPERTIES CO , SLADE HERBERT B , GUY CYNTHIA A
发明人： SLADE HERBERT B , GUY CYNTHIA A
IPC分类号： A61K39/385
CPC分类号： C07D471/04 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0073 , A61K9/02 , A61K9/06 , A61K31/437 , A61K31/4745 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/34
摘要： A method of treating disease with immune response modifier (IRM) compounds by using at least two different routes of administration, such as administering at least one IRM to a subject locally (e.g., topically) at a disease site in combination with separately administering at least one IRM to the subject systemically (e.g., orally or by injection).
摘要翻译：一种利用免疫应答调节剂（IRM）化合物通过使用至少两种不同给药途径来治疗疾病的方法，例如在疾病部位局部（例如局部）向受试者施用至少一种IRM，并且至少单独施用至少系统地（例如，口头或注射）一个IRM。

3. 发明申请

WO2008118765A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118765A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057761
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。咪喹莫特的局部和/或透皮递送，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性软疣，病毒感染如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，并诱导干扰素生物合成。

4. 发明申请

WO2008118762A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118762A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057758
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat chiidren affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatologica! disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了用于增强咪喹莫特用于治疗受皮肤疾病影响的儿童的安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。局部和/或透皮给药咪喹莫特，包括霜剂，软膏，凝胶，洗剂，药膏和压敏胶粘剂组合物以治疗皮肤病！公开了儿童疾病，即传染性软体动物，病毒感染，例如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

5. 发明申请

WO2008118881A1 METHOD AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：使用IMIQUIMOD治疗患有皮肤病的儿童治疗儿童时，加强安全的方法和包装
公开(公告)号：WO2008118881A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/058070
申请日：2008-03-24
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type 1 or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L本文和/或透皮给药咪喹莫特，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性软疣，病毒感染例如1型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

6. 发明申请

WO2008118763A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118763A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057759
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC. , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, moiluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal ceil carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。咪喹莫特的局部和/或透皮递送，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性疾病，病毒感染如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，并诱导干扰素生物合成。

7. 发明申请

WO2006073940A2 MULTI-ROUTE ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS 审中-公开
标题翻译：免疫反应调节剂化合物的多路径管理
公开(公告)号：WO2006073940A2
公开(公告)日：2006-07-13
申请号：PCT/US2005/047069
申请日：2005-12-28
申请人： 3M INNOVATIVE PROPERTIES COMPANY , SLADE, Herbert, B. , GUY, Cynthia, A.
发明人： SLADE, Herbert, B. , GUY, Cynthia, A.
IPC分类号： A61K31/4745
CPC分类号： C07D471/04 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0073 , A61K9/02 , A61K9/06 , A61K31/437 , A61K31/4745 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/34 , Y02A50/481
摘要： A method of treating disease with immune response modifier (IRM) compounds by using at least two different routes of administration, such as administering at least one IRM to a subject locally (e.g., topically) at a disease site in combination with separately administering at least one IRM to the subject systemically (e.g., orally or by injection).
摘要翻译：通过使用至少两种不同的给药途径来治疗疾病的方法，例如对疾病局部（例如局部）给予至少一种IRM治疗疾病结合单独给予至少一种IRM（例如口服或通过注射）给受试者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式